Expression of AFP and STAT3 Is Involved in Arsenic Trioxide-Induced Apoptosis and Inhibition of Proliferation in AFP-Producing Gastric Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Jia, Yanfei ^a   Liu, Dezhi ^b   Xiao, Dongjie ^a   Ma, Xiaoli ^a   Han, Shuyi ^a   Zheng, Yan ^a   Sun, Shanhui ^a   Zhang, Maoxiu ^a   Gao, Hongmei ^a   Cui, Xia ^a   Wang, Yunshan ^a  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ARSENIC TRIOXIDE; PROTEIN BAX; STAT3 PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAX GENE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ALPHA-FETOPROTEINS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXIDES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 84873812790     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054774     Document Type: Article

References (48)

1. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, et al. (2012) Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. Journal of Surgical Oncology 102: 249-255.
2. Isonishi S, Ogura A, Kiyokawa T, Suzuki M, Kunito S, et al. (2009) Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman. Int J Clin Oncol. 14: 70-73.
3. Hamanaka W, Yoneda S, Shirakusa T, Shirahama H, Tashiro Y, et al. (2008) Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma-long survival with various therapeutic strategies including a lung resection: Report of a case. Surg Today. 38: 275-278.
4. Yamagata T, Yamagata Y, Nakanishi M, Matsunaga K, Minakata Y, et al. (2004) A case of primary lung cancer producing alpha-fetoprotein. Can Respir J. 11: 504-506.
5. Ueno M, Nakashima J, Ohigashi T, Deguchi N, Ban S, et al. (2001) Establishment of a testicular carcinoma cell line producing alpha-fetoprotein. BJU Int. 88: 611-621.
6. Saito S, Hatano T, Hayakawa M, Koyama Y, Ohsawa A, et al. (1989) Studies on alpha-fetoprotein produced by renal cell carcinoma. Cancer. 63: 544-549.
7. Hocking GR, Shembrey M, Hay D, Ostör AG, (1995) Alpha-fetoprotein producing adenocarcinoma of the sigmoid colon with possible hepatoid differentiation. Pathology. 27: 277-279.
8. Dhar DK, Kubota H, Tabara H, Kotoh T, Monden N, et al. (1999) Nm23 in the primary and metastatic sites of gastric carcinoma. Oncology. 56: 122-128.
9. Chang YC, Nagasue N, Kohno H, Taniura H, Uchida M, et al. (1990) Clinicopathologic features and long term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol. 85: 1480-1485.
10. Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, et al. (2002) Clinicopahtologic features of gastric cancers producing alpha-fetoprotein. Dig Surg. 19: 359-365.
11. Emadi A, Gore SD, (2010) Arsenic trioxide- An old drug rediscovered, Blood Rev. 24: 191-199.
12. Yedjou C, Tchounwou P, Jenkins J, McMurray R, (2010) Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol. 3: 28-36.
13. Lafayette TC, Coser VM, Brûlé AO, Coser PL, Pereira WV, (2010) External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature. J Pediatr Hematol Oncol. 32: 229-232.
14. Wu DD, Xiao YF, Geng Y, Hou J, (2010) Antitumor effect and mechanisms of arsenic trioxide on subcutaneously implanted human gastric cancer in nude mice. Cancer Genetics and Cytogenetics. 19: 890-896.
15. Izdebska M, Grzanka A, Szczepański MA, Litwiniec A, (2008) Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment. Postepy Hig Med Dosw. 62: 463-467.
16. Gao F, Yi J, Shi GY, Li H, Shi XG, et al. (2002) The sensitivity of digestive tract tumor cells to As2O3 is associated with the inherent cellular level of reactive oxygen species. World J Gastroenterol 8: 36-39.
17. Bowling BD, Doudican N, Manga P, Orlow SJ, (2008) Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism, Cancer Chemother Pharmacol. 63: 37-43.
18. Florea AM, Busselberg D, (2009) Anti-cancer drugs interfere with intracellular calcium signaling. Neurotoxicology (30):: 803-810.
19. Gonda T, Ishida H, Higuchi T, Hirukawa H, Nakajima H, et al. (1994) A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with EAP (etoposide, adriamycin,cisplatin) therapy. Jpn J Cancer Chemother. 21: 1659-1663.
20. Hoshino K, Kawaguchi H, Unate H, Nitta K, Fukui H, et al. (1996) A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP. Jpn J Cancer Chemother. 23: 1197-1200.
21. Yabusaki H, Nashimoto A, Tanaka O, (2000) A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy. Jpn J Cancer Chemother. 27: 735-738.
22. James E, Darnell J, (1997) STATs and gene regulation. Science 277: 1630-1635.
23. Levy DE, Darnell JE, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol. Cell Biol 3: 651-662.
24. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, (2009) Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell. 4: 283-293.
25. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10: 105-115.
26. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res 12: 9-11.
27. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, et al. (2008) Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 172: 1717-1728.
28. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, et al. (2009) Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis. 30: 1848-1856.
29. Kim DY, Cha ST, Ahn DH, Kang HY, Kwon C, et al. (2009) STAT3 expression in gastric cancer indicates a poor prognosis, Journal of Gastroenterology and Hepatology. 24: 646-651.
30. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, et al. (2004) Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 23: 5426-5434.
31. Zhang F, Li C, Halfter H, Liu J, (2003) Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene. 22: 894-905.
32. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene. 21: 2000-2008.
33. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine. 339: 1341-1348.
34. Siu KP, Chan JY, Fung KP, (2002) Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction of apoptosis. Life Sciences. 71: 275-285.
35. Jiang W, Feng JF, Pan LG, Huang XE, Chen J, (2006) A clinical study of arsenic trioxide injection in treatment of advanced primary carcinoma of the liver, Journal of basic and clinical oncology. l19: 21-23.
36. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 89: 3354-3360.
37. Dudich E, Semenkova L, Gorbatova E, Dudich I, Khromykh L, et al. (1998) Growth- regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumour Biol. 19: 30-40.
38. Wang XW, Xu B, (1998) Stimulation of tumor- cell growth by alpha-fetoprotein. Int J Cancer. 75: 596-599.
39. Wang YS, Ma XL, Qi TG, Liu XD, Meng YS, et al. (2005) Downregulation of alpha-fetoprotein siRNA inhibits proliferation of SMMC-7721 cells. World J Gastroenterol. 11: 6053-6055.
40. Sumi D, Shinkai Y, Kumagai Y, (2010) Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicology and Applied Pharmacology. 244: 385-392.
41. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, et al. (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 1: 851-860.
42. Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, et al. (2006) Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 12: 6817-6825.
43. Li M, Li H, Li C, Guo L, Liu H, et al. (2009) Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett. 285: 190-199.
44. Li M, Li H, Li C, Zhou S, Guo L, et al. (2009) Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer. 124: 2845-2854.
45. Nielsen M, Kaestel CG, Eriksen KW, Woetmann A, Stokkedal T, et al. (1999) Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 13: 735-738.
46. Kroemer G, Zamzami N, Susin SA, (1997) Mitochondrial control of apoptosis. Immunol Today 18: 44-51.
47. Kataoka H, Miura Y, Joh T, Seno K, Tada T, et al. (2001) Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1. Oncogene. 20: 869-873.
48. Nojiri S, Joh T, Miura Y, Sakata N, Nomura T, et al. (2004) ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. Biochemical and Biophysical Research Communications. 314: 97-103.